Publications

• NYAG’s PFAS Suit: Litigation Defense Strategies for Consumer Product Manufacturers
  19 August 2026
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kimberly Anker
  ,
  Cara Maines
  ,
  Kaitlyn McGill
• NYAG’s PFAS Suit: Lessons for Investors
  7 August 2026
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kimberly Anker
  ,
  Cara Maines
  ,
  Kaitlyn McGill
• Private Equity Report Fall 2025, Vol 25, No 3
  November 2025
  Christopher Anthony
  ,
  Vadim Avdeychik
  ,
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  Tim Cornell
  ,
  Morgan A. Davis
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Uri Herzberg
  ,
  Eric T. Juergens
  ,
  Maura Kathleen Monaghan
  ,
  Gordon Moodie
  ,
  Sheena Paul
  ,
  Marc Ponchione
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Christopher S. Ford
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Kate Saba
  ,
  Daniel Jaret
  ,
  Adriana Kranjac Rielly
  ,
  Kaitlyn McGill
  ,
  Amy Pereira
• Liability Transfer Transactions: Opportunities for Funds Buying and Selling Mass Tort Exposure
  November 2025
  Morgan A. Davis
  ,
  Mark P. Goodman
  ,
  Andrew G. Jamieson
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Adriana Kranjac Rielly
  ,
  Kaitlyn McGill
• The Food and Drug Administration Under the Second Trump Administration
  18 June 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
• New Combination Drugs: Assessing the Potential Impact of New CMS Draft Guidance on Pharmaceutical Companies and Investors
  27 May 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Unpacking President Trump’s New Executive Order on “Most-Favored-Nation” Prescription Drug Pricing
  20 May 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Unpacking President Trump’s New Executive Order on Prescription Drug Pricing
  24 April 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Supreme Court Opens the Door to RICO Claims Arising from Personal Injuries — but with Significant Limitations
  8 April 2025
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Healthcare Policy in Flux: The Impact of Trump Administration Changes to HHS
  28 March 2025
  Josh A. Cohen
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Jane Shvets
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Anu Chugh
  ,
  Robin Fisher
  ,
  Kate Saba
  ,
  Stuart Crews
  ,
  Swati Mehrotra
• First Circuit Affirms Causation Defense for False Claims Act Based on AKS Violations
  3 March 2025
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• The Eleventh Circuit Invalidates TCPA Rules:
  Lessons for Companies Subject to the TCPA and Administrative Law
  30 January 2025
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Top 10 Healthcare and Life Sciences Issues to Watch in 2025
  10 January 2025
  Andrew L. Bab
  ,
  Tim Cornell
  ,
  Avi Gesser
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Erez Liebermann
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Jane Shvets
  ,
  Patrick Taylor
  ,
  Erica S. Weisgerber
  ,
  Carter Burwell
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Lillian Lara
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac Rielly
  ,
  James Lapp
  ,
  Hannah R. Levine
  ,
  Kaitlyn McGill
  ,
  Adam C. Saunders
  ,
  Mackenzie Mendolla
• California Judge Allows Public Nuisance Claims Against Social Media Companies
  22 November 2024
  Lindsay Cooper Hayman
  ,
  Maura Kathleen Monaghan
  ,
  Abraham Tabaie
  ,
  Carter Burwell
  ,
  Jacob W. Stahl
  ,
  Kaitlyn McGill
• Westlaw: The Death of Chevron: Implications of the Loper Decision for Public Companies
  17 September 2024
  Westlaw
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• MarketCheck – Summer 2024
  August 2024
  Andrew L. Bab
  ,
  Gregory V. Gooding
  ,
  Jyotin Hamid
  ,
  Emily F. Huang
  ,
  Stephen Jordan
  ,
  Maurizio Levi-Minzi
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Jeffrey J. Rosen
  ,
  Zachary H. Saltzman
  ,
  Shannon Rose Selden
  ,
  Matthew J. Sorensen
  ,
  Katherine Durnan Taylor
  ,
  Alison E. Buckley-Serfass
  ,
  Caitlin Gibson
  ,
  Anne-Mette Heemsoth
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jillian Mulroy Wright
  ,
  Ilya Balabanovsky
  ,
  Marisa Demko
  ,
  Rekha Korlipara Kreider
• 2024 Private Equity Midyear Outlook
  August 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Christopher Dortschy
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Arian M. June
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Gregory J. Lyons
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Sheena Paul
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Paul D. Rubin
  ,
  Scott B. Selinger
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Rick Sofield
  ,
  Katherine Durnan Taylor
  ,
  Ramya S. Tiller
  ,
  Jonathan R. Tuttle
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Jennifer Wheater
  ,
  Naomi Aoyama
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Jennifer R. Cestaro
  ,
  Robert T. Dura
  ,
  Paul Eastham
  ,
  Stuart Hammer
  ,
  Lauren P. Heller
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  John Young
  ,
  Ulysses Smith
  ,
  Kayleigh Anderson
  ,
  Hymie A. Anteby
  ,
  Jabari Benjamin
  ,
  Josephine Chen
  ,
  Jordan Corrente Beck
  ,
  Julia Needle
  ,
  Michael C. Godbe
  ,
  Zoe Jacoby
  ,
  Yiran Ji
  ,
  Adriana Kranjac Rielly
  ,
  Paul D. Lowry
  ,
  Kaitlyn McGill
  ,
  Amy Pereira
  ,
  Eike Björn Weidner
  ,
  Keith Moshe
• Law360: After Chevron: FDA Regulations In The Crosshairs
  8 July 2024
  Law360
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• Increased FCA Enforcement Targeting PE Firms Expected in 2024
  11 March 2024
  Helen V. Cantwell
  ,
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Shannon Rose Selden
  ,
  Jacob W. Stahl
  ,
  Kaitlyn McGill
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac Rielly
  ,
  Kaitlyn McGill
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Ilya Balabanovsky
  ,
  Margaret Howard
  ,
  James Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• Law360: What Banks Should Know About TCPA Exam Policy Updates
  13 December 2023
  Law360
  Maura Kathleen Monaghan
  ,
  Caroline N. Swett
  ,
  Jacob W. Stahl
• OCC Issues Revised TCPA Examination Procedures: What Bank Compliance Personnel Should Know
  15 November 2023
  Helen V. Cantwell
  ,
  Courtney M. Dankworth
  ,
  Maura Kathleen Monaghan
  ,
  Caroline N. Swett
  ,
  Jacob W. Stahl
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• 2023 Private Equity Midyear Outlook
  27 July 2023
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Jeffrey P. Cunard
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Emily F. Huang
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  Rafael Kariyev
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Julie M. Riewe
  ,
  Shannon Rose Selden
  ,
  Steven J. Slutzky
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  J. Michael Snypes, Jr.
  ,
  Patrick Taylor
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Erica S. Weisgerber
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Robert T. Dura
  ,
  Stuart Hammer
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Jacob W. Stahl
  ,
  Sergio Torres
  ,
  Jennifer Wheater
  ,
  Elie J. Worenklein
  ,
  Colleen B. Bernaiche
  ,
  Paul Eastham
  ,
  Christopher Gossage
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Rekha Korlipara Kreider
  ,
  Adriana Kranjac Rielly
  ,
  Samuel D. Krawiecz
  ,
  Megan MacDonald
  ,
  Harshil Mehta
  ,
  Stanley G. Seckler
  ,
  Sheng Shao
  ,
  Massy Vainshtein
  ,
  Kimberly Anker
• Legal Dispute Surrounding Abortion Pill Has Significant Implications for Broader Healthcare Industry
  9 May 2023
  Andrew L. Bab
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Micah A. Rubin
• Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
  November 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
  19 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Recent SCOTUS Decisions Impacting Healthcare
  3 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
  16 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Adriana Kranjac Rielly
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• 2021/2022 Private Equity Year-End Review and Outlook
  January 2022
  Jonathan Adler
  ,
  Catherine Amirfar
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Geoffrey P. Burgess
  ,
  Ezra Borut
  ,
  Andrew J. Ceresney
  ,
  Jeffrey P. Cunard
  ,
  Alexander R. Cochran
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Morgan J. Hayes
  ,
  Eric T. Juergens
  ,
  Maurizio Levi-Minzi
  ,
  Nicholas P. Pellicani
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Scott B. Selinger
  ,
  Marc Ponchione
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Christopher Dortschy
  ,
  Emily F. Huang
  ,
  Jennifer Wheater
  ,
  Dominic Blaxill
  ,
  Robert T. Dura
  ,
  Matthew J. Sacco
  ,
  Sheng Shao
  ,
  Sergio Torres
  ,
  Paul Eastham
  ,
  Christopher Gossage
  ,
  Robert B. Kaplan
  ,
  Sheena Paul
  ,
  John Young
  ,
  Jin-Hyuk Jang
  ,
  Lukas Ott
  ,
  Andrew M. Levine
  ,
  Stuart Hammer
  ,
  Ulysses Smith
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Peter J. Irwin
  ,
  Ina Popova
  ,
  Samantha J. Rowe
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Paul D. Rubin
  ,
  Eric Dinallo
  ,
  Marilyn A. Lion
  ,
  Jacob W. Stahl
  ,
  Nicholas F. Potter
  ,
  Melissa Runsten
  ,
  Matthew Mrozek
  ,
  Michael C. Godbe
  ,
  Christel Y. Tham
  ,
  Lisa Wang Lachowicz
  ,
  Yiran Ji
• 2021 Private Equity Midyear Review and Outlook
  22 July 2021
  Jonathan Adler
  ,
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Andrew L. Bab
  ,
  Megan K. Bannigan
  ,
  Sally Bergmann Hardesty
  ,
  David H. Bernstein
  ,
  Paul S. Bird
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Matthew Dickman
  ,
  Christopher Dortschy
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Peter A. Furci
  ,
  Avi Gesser
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Rafael Kariyev
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Paul D. Rubin
  ,
  Zachary H. Saltzman
  ,
  Kevin M. Schmidt
  ,
  Shannon Rose Selden
  ,
  Scott B. Selinger
  ,
  Steven J. Slutzky
  ,
  Ramya S. Tiller
  ,
  Richard Ward
  ,
  Patricia Volhard
  ,
  Franci J. Blassberg
  ,
  Jeffrey P. Cunard
  ,
  Stuart Hammer
  ,
  Jin-Hyuk Jang
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  Jennifer Wheater
  ,
  John Young
  ,
  Dominic Blaxill
  ,
  Robert T. Dura
  ,
  Paul Eastham
  ,
  David J. Hotelling
  ,
  Samuel D. Krawiecz
  ,
  Wen-Wei Lai
  ,
  Robert Maddox
  ,
  Sergio Torres
• The Supreme Court TransUnion Case: Part 2—What It Means for Efforts to Defeat Class Certification?
  9 July 2021
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jacob W. Stahl
• Law360: Lessons From Federal Fraud Charges Against UBiome
  16 April 2021
  Law360
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Hannah R. Levine
• Law360: TCPA Litigation And Compliance After Facebook Ruling
  13 April 2021
  Law360
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• The Supreme Court Rules for Facebook: What It Means for TCPA Compliance and Class Certification Defense
  7 April 2021
  Courtney M. Dankworth
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Pharm Exec: The American Rescue Plan Act of 2021: Pharmaceutical Industry Impact
  23 March 2021
  Pharm Exec
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Eleventh Circuit Precludes “Administrative Feasibility” but Provides a Path Forward for Defendants Opposing Class Certification in Consumer Class Actions
  9 February 2021
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• 2020/2021 Private Equity Year End Review and Outlook
  7 January 2021
  Jonathan Adler
  ,
  William D. Regner
  ,
  John W. Rife III
  ,
  Jennifer R. Cestaro
  ,
  Katherine Ashton
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Thomas Smith
  ,
  Ramya S. Tiller
  ,
  Christopher Anthony
  ,
  Kevin M. Schmidt
  ,
  Maurizio Levi-Minzi
  ,
  Geoffrey P. Burgess
  ,
  Dominic Blaxill
  ,
  Wen-Wei Lai
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Steven J. Slutzky
  ,
  Richard Ward
  ,
  Jennifer Wheater
  ,
  Paul Eastham
  ,
  Peter A. Furci
  ,
  Rafael Kariyev
  ,
  Samuel D. Krawiecz
  ,
  Andrew L. Bab
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Jyotin Hamid
  ,
  Jonathan F. Lewis
  ,
  Tricia Bozyk Sherno
  ,
  Ezra Borut
  ,
  Jeffrey P. Cunard
  ,
  Marc Ponchione
  ,
  Kenneth J. Berman
  ,
  Patricia Volhard
  ,
  Christopher Dortschy
  ,
  Jin-Hyuk Jang
  ,
  John Young
  ,
  Andrew J. Ceresney
  ,
  Robert B. Kaplan
  ,
  Julie M. Riewe
  ,
  Sally Bergmann Hardesty
  ,
  Scott B. Selinger
  ,
  Stuart Hammer
  ,
  Luke Dembosky
  ,
  Avi Gesser
  ,
  Jim Pastore
  ,
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  M. Natasha Labovitz
  ,
  Sidney P. Levinson
  ,
  Peter J. Irwin
  ,
  Paul S. Bird
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Federal Government Shines Spotlight on Speaker Programs
  20 November 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Law360: Trump's Drug Pricing Order Is More Bark Than Bite
  22 September 2020
  Law360
  Paul D. Rubin
  ,
  Jacob W. Stahl
• Providers, Investors Need Clear Post-COVID Telehealth Picture
  22 September 2020
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Bloomberg Law: Providers, Investors Need Clear Post-Covid Telehealth Picture
  16 September 2020
  Bloomberg Law
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Bloomberg Law: Providers, Investors Need Clear Post-Covid Telehealth Picture
  16 September 2020
  Bloomberg Law
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
  29 July 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Supreme Court Acts Twice on the TCPA: What It Means for Automated Callers, the First Amendment, and Statutory Challengers
  10 July 2020
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Update Regarding Public Health and Social Services Emergency Fund
  6 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: CMS Expands Medicare Coverage for Telehealth Services amid Public Health Emergency
  20 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: FDA Developments and Legal Considerations for Healthcare and Life Science Companies and Investors
  17 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Law360: How Tax Reform Could Impact the Health Care Industry
  15 November 2017
  Andrew L. Bab
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl